Skip to main content
Rheumatology Salaries 2025

Medscape has published its annual Physician Compensation report with physican salaries up r

Dr. John Cush RheumNow

5 months ago
Rheumatology Salaries 2025 Medscape has published its annual Physician Compensation report with physican salaries up roughly 3% and eight specialties earning more than $500,000 per annum. https://t.co/DNe42EsxRW https://t.co/aegcNm8Pla
Severe thrombocytopenia (TP) assoc w/ severe APS & increased mortality. Retro study of 432 #APS pts - 142 w/ TP (33

Dr. John Cush RheumNow

5 months ago
Severe thrombocytopenia (TP) assoc w/ severe APS & increased mortality. Retro study of 432 #APS pts - 142 w/ TP (33%): 13% severe TP (<50L G/L). Severe TP assoc w/ ITP & CAP -had higher mortality https://t.co/7f8VpIcEJy
Weight-loss drugs may affect joints directly

A new study from Aarhus University shows that the hormone GLP-1, which is

Dr. John Cush RheumNow

5 months ago
Weight-loss drugs may affect joints directly A new study from Aarhus University shows that the hormone GLP-1, which is mimicked in medication for diabetes and weight loss, is present in joint fluid. In the long term, this may open up new treatments for arthritis. https://t.co/HkcPUQp05H
Does monotherapy work? network meta-analysis of 31 RCTs, 13 csDMARDs, Leflunomide, SSZ & gold were better than plac

Dr. John Cush RheumNow

5 months ago
Does monotherapy work? network meta-analysis of 31 RCTs, 13 csDMARDs, Leflunomide, SSZ & gold were better than placebo & equal to MTX regarding annual xray progression scores. Evidence in favor BUT failed to study monoRx vs Combo Rx https://t.co/cMSZ4QHi5G https://t.co/o9ikhJu3UM
NSAIDs in Inflammatory Bowel Disease?

At least some patients with inflammatory bowel disease (IBD) can safely use comm

Dr. John Cush RheumNow

5 months ago
NSAIDs in Inflammatory Bowel Disease? At least some patients with inflammatory bowel disease (IBD) can safely use common drugs for musculoskeletal aches and pains, a large study of insurance claims data suggested, contradicting a widespread concern that these products can https://t.co/JeINgTWTK0
ACR Endorses New Training Model for Pediatric Subspecialties

The ACR welcomes the recent announcement from the America

Dr. John Cush RheumNow

5 months ago
ACR Endorses New Training Model for Pediatric Subspecialties The ACR welcomes the recent announcement from the American Board of Pediatrics (ABP) outlining new training models for pediatric subspecialties. Given the collaborative work ACR has engaged in over the years, this is https://t.co/blNkWXuLkJ
TriNetX study of 7,929 RA pts Rx w/ bDMARDs (n 2668) w/in 6 mos of elective hand surgery - perioperative bDMARD continua

Dr. John Cush RheumNow

5 months ago
TriNetX study of 7,929 RA pts Rx w/ bDMARDs (n 2668) w/in 6 mos of elective hand surgery - perioperative bDMARD continuation (34%) was not associated with significant increases in risks of wound healing failures (1.4% vs 1.4%) or SSI (2% vs 1.5%) https://t.co/NY6l2jRswb https://t.co/IxoYtLNGvf
GI involvement occurs in 37-65% of adult IgA (IgAV) cases, w/ Sxs of abdominal pain, hematochezia, severe complications

Dr. John Cush RheumNow

5 months ago
GI involvement occurs in 37-65% of adult IgA (IgAV) cases, w/ Sxs of abdominal pain, hematochezia, severe complications of perforation & ischemia. Dx w/ CRP, NLR, D-dimer, imaging (CT, endoscopy). Steroids w/ Mod-to-severe Dz. MMF or IVIG for refractory cases. https://t.co/vgvZnYXIOI
Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova

In this https://t.co/4U

Dr. John Cush RheumNow

5 months ago
Mortality in Rheumatoid Arthritis: A Story of Decline, Delay, or Plateau? Dr. Elena Myasoedova In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Elena Myasoedova examines mortality trends in RA, exploring whether we are seeing continued decline, delayed impact, or a concerning https://t.co/yUob3Tv0tR
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week. 
Citrullinated histone H3 (CitH3) (from PMN extracellular traps - possible marker of PMN activation) studied in 65 MPA/GP

Dr. John Cush RheumNow

5 months ago
Citrullinated histone H3 (CitH3) (from PMN extracellular traps - possible marker of PMN activation) studied in 65 MPA/GPA pts. CitH3 signif correlated w/ BVAS (r 0.393) & ESKD risk (adj HR 1.181) https://t.co/kyNzCTUCKD https://t.co/DdMvbBBSdk
DESIR axSpA inception cohort study of 631 pts (no HTN), found no signif association between NSAID use & incident HTN

Dr. John Cush RheumNow

5 months ago
DESIR axSpA inception cohort study of 631 pts (no HTN), found no signif association between NSAID use & incident HTN. Over 10 YRs, 88 developed HTN (HR 1.01, 1.00–1.02) https://t.co/Gs9mPwthEj https://t.co/4sfpHmFTsu
Chinese study of 371 pts w/ Autoimmune hepatitis (AIH) - extrahepatic autoimmune diseases (EADs) seen in 24% -Sjogren’

Dr. John Cush RheumNow

5 months ago
Chinese study of 371 pts w/ Autoimmune hepatitis (AIH) - extrahepatic autoimmune diseases (EADs) seen in 24% -Sjogren’s & autoimmune thyroid dz (9% each). ANA+ independently assoc w/ EADs (OR 2) https://t.co/NVz8MWbJch https://t.co/tjCzaDcUFI
Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transpla

Dr. John Cush RheumNow

5 months 1 week ago
Chinese target emulation trial of MDA-5+, dermatomyositis w/ ILD. 106 Rx w/ UPA & 328 w/ TOFA. 6-month lung transplantation-free survival 72% vs 67% (UPA v TOFA). UPA non-inferior to TOFA in MDA5+DM-ILD https://t.co/BBAfbM06AM https://t.co/QP8YdX7CcH
×